The State of Psychedelics: science, policy shifts, and how MDMA and psilocybin are entering mental health care

Psychedelics are moving from taboo status to mainstream mental health care, with the article weighing both their therapeutic promise and the risks that come with hype. The piece connects FDA review and clinical research with shifting state laws and growing demand for supervised, guided sessions. It frames a key theme as context: mindset, setting, and expert support are portrayed as central to outcomes, while warnings emphasize that real-world effectiveness and safety may differ from early, tightly controlled trials. Through interviews and examples, the article highlights leading indications and study designs. It discusses MDMA-assisted therapy for PTSD in veterans, including MAPS-funded trial outcomes and public policy momentum, and also covers psilocybin studies for depression and addiction, including an NYU alcohol-abstinence trial using structured sessions with psychotherapy. It contrasts these controlled approaches with concerns about underground or unsupervised use and other dangers in the broader cultural wave around psychedelic medicine.